All In Biotech

Drug Trial Radar · NCT03955445

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Iptacopan (LNP023) in C3 Glomerulopathy or Idiopathic Immune-complex-membranoproliferative Glomerulonephritis

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Oct 3, 2019

Primary completion

May 30, 2036

Study completion May 30, 2036

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Conditions

  • C3 Glomerulopathy
  • Immune-complex-membranoproliferative Glomerulonephritis

Interventions

  • LNP023Drug

    LNP023 capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CLNP023X2202 Cohort A-native C3G: Number of participants who achieve the composite renal endpointTime frame: 9-month visit
  2. CLNP023X2202 Cohort B - kidney transplant and recurrent C3G: Change from baseline in the C3 Deposit ScoreTime frame: 6 - to 9- month visit
  3. Number of AEs of special interest for participants from CLNP023X2202, CLNP023B12301 and CLNP023B12302Time frame: Participants are expected to continue on study for a minimum of 60 months and a maximum of 84 months
  4. Number of participants with study drug discontinuation due to an AE (or any safety issue) for participants from CLNP023X2202, CLNP023B12301 and CLNP023B12302Time frame: Participants are expected to continue on study for a minimum of 60 months and a maximum of 84 months
  5. Number of participants with abnormal clinically significant vital signs,ECGs, and safety laboratory measurements for participants from CLNP023X2202, CLNP023B12301 and CLNP023B12302Time frame: Participants are expected to continue on study for a minimum of 60 months and a maximum of 84 months

Locations

53 sites in 17 countries. Site status is shown where the registry gives one.

  • Childrens Hospital Colorado

    Aurora, Colorado · Recruiting

  • Georgia Nephrology Research Inst

    Lawrenceville, Georgia · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Col Uni Med Center New York Presby

    New York, New York · Recruiting

  • Novartis Investigative Site

    Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Salvador, Brazil · Recruiting

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Botucatu, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Active not recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Active not recruiting

  • Novartis Investigative Site

    Montpellier, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Active not recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Toulouse, France · Recruiting

  • Novartis Investigative Site

    Erlangen, Germany · Active not recruiting

  • Novartis Investigative Site

    Essen, Germany · Recruiting

  • Novartis Investigative Site

    Hamburg, Germany · Active not recruiting

  • Novartis Investigative Site

    Heidelberg, Germany · Recruiting

  • Novartis Investigative Site

    Mainz, Germany · Recruiting

  • Novartis Investigative Site

    Heraklion Crete., Greece · Active not recruiting

  • Novartis Investigative Site

    Thessaloniki, Greece · Active not recruiting

  • Novartis Investigative Site

    Petah Tikva, Israel · Recruiting

  • Novartis Investigative Site

    Petah Tikva, Israel · Active not recruiting

  • Novartis Investigative Site

    Bari, BA, Italy · Recruiting

  • Novartis Investigative Site

    Ranica, BG, Italy · Recruiting

  • Novartis Investigative Site

    Roma, RM, Italy · Recruiting

  • Novartis Investigative Site

    Niigata, Japan · Active not recruiting

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan · Active not recruiting

  • Novartis Investigative Site

    Asahikawa, Hokkaido, Japan · Active not recruiting

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan · Completed

  • Novartis Investigative Site

    Takatsuki, Osaka, Japan · Active not recruiting

  • Novartis Investigative Site

    Ohtsu, Shiga, Japan · Recruiting

  • Novartis Investigative Site

    Hachiōji, Tokyo, Japan · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.